Company Isofol Medical AB (publ) Nasdaq Stockholm
Equities
SE0009581051
Pharmaceuticals
Business Summary
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Arfolitixorin
100.0
%
| 13 | 100.0 % | 1 | 100.0 % | -94.37% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Asia
100.0
%
| 13 | 100.0 % | 1 | 100.0 % | -94.37% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Petter Lindqvist
CEO | Chief Executive Officer | 72 | 01-08 |
Magnus Hurst
DFI | Director of Finance/CFO | 68 | 01-09 |
Roger Tell
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-01-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Lars Erik Lind
CHM | Chairman | 83 | - |
Sten Nilsson
BRD | Director/Board Member | 76 | 01-03 |
Alain Herrera
BRD | Director/Board Member | 74 | 17-12-31 |
79 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 161,515,440 | 101,064,675 ( 62.57 %) | 0 | 62.57 % |
Company contact information
Isofol Medical AB
Biotech Center Arvid Wallgrens Backe 20
413 46, Gothenburg
+46 3 17 97 22 80
http://www.isofol.seSector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+16.93% | 79.28B | |
+7.97% | 8.74B | |
-17.73% | 4.84B | |
+56.03% | 4.74B | |
+1.31% | 3.87B | |
+18.99% | 2.46B | |
-25.43% | 2.18B | |
+14.61% | 2.09B | |
-37.31% | 1.98B |